Price
$2.97
Increased by +1.37%
Dollar volume (20D)
1.93 M
ADR%
10.60
Shares float
31.13 M
Shares short
2.32 M [7.44%]
Shares outstanding
49.09 M
Market cap
156.38 M
Beta
0.78
Price/earnings
N/A
20D range
2.60 4.94
50D range
2.60 6.22
200D range
2.60 9.69

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.

The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.

In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2.

It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 12, 24 -0.25
Decreased by -4.17%
-0.29
Increased by +14.32%
Aug 12, 24 -0.28
Increased by +45.10%
-0.28
Increased by +1.34%
May 13, 24 -0.32
Increased by +65.59%
-0.26
Decreased by -23.08%
Mar 6, 24 -0.21
Increased by +73.08%
-0.29
Increased by +27.59%
Nov 9, 23 -0.24
Increased by +64.18%
-0.45
Increased by +46.67%
Aug 10, 23 -0.51
Increased by +19.05%
-0.78
Increased by +34.62%
May 10, 23 -0.93
Decreased by -38.81%
-0.74
Decreased by -25.68%
Mar 8, 23 -0.78
Decreased by -105.26%
-0.70
Decreased by -11.43%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 1.05 M
Decreased by -73.01%
-29.89 M
Decreased by -29.96%
Decreased by -2.85 K%
Decreased by -381.56%
Jun 30, 24 536.00 K
Decreased by -82.97%
-31.66 M
Decreased by -31.67%
Decreased by -5.91 K%
Decreased by -673.34%
Mar 31, 24 566.00 K
Decreased by -91.68%
-30.14 M
Decreased by -33.59%
Decreased by -5.33 K%
Decreased by -1.51 K%
Dec 31, 23 7.21 M
Increased by +721.00 K%
-19.61 M
Decreased by -4.34%
Decreased by -271.99%
Increased by +99.99%
Sep 30, 23 3.89 M
Increased by +15.58%
-23.00 M
Decreased by -44.53%
Decreased by -591.64%
Decreased by -25.04%
Jun 30, 23 3.15 M
Decreased by -22.39%
-24.05 M
Decreased by -60.86%
Decreased by -763.82%
Decreased by -107.25%
Mar 31, 23 6.80 M
Increased by +125.19%
-22.56 M
Decreased by -39.72%
Decreased by -331.66%
Increased by +37.96%
Dec 31, 22 1.00 K
Decreased by -99.96%
-18.80 M
Decreased by -32.37%
Decreased by -1.88 M%
Decreased by -377.69 K%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY